Proteins circulating in men's blood could reveal a heightened risk of prostate cancer more than a decade and a half before any clinical diagnosis, according to a new study from the University of Oxford. The findings, published in European Urology, offer a window into the earliest biological changes that precede the disease, and may eventually help clinicians distinguish between slow-growing tumours and those that turn deadly.
Prostate cancer is the most frequently diagnosed cancer among men in the European Union, with roughly 330,000 new cases and around 75,000 deaths each year across the bloc. It ranks as the second most common cancer worldwide, after lung cancer. The new research, led by scientists at Oxford Population Health, focused on identifying molecular clues that appear long before symptoms or screening would typically catch the disease.
Mining decades-old blood samples
The team analysed blood plasma collected between 1992 and 2000 from more than 2,500 men. Among them, 982 men later developed prostate cancer, while 1,573 remained cancer-free. By measuring over 6,000 different proteins in each sample, the researchers could compare the protein profiles of those who went on to develop the disease with those who did not, sometimes looking back more than 15 years before diagnosis.
“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford. The results revealed that certain proteins were associated with an elevated overall risk of prostate cancer, while others were specifically tied to aggressive or fast-growing forms of the disease.
Interestingly, higher levels of some immune-system proteins, such as GZMK and ANXA2, appeared to correlate with a lower long-term risk. This suggests that the immune system may play a protective role in some men, a nuance that could shape future prevention strategies.
Toward better risk assessment
“Many prostate cancers grow slowly and may never cause harm, while others are aggressive and can be life-threatening,” said Zhe Huang, first author of the study and a postdoctoral epidemiologist at Oxford Population Health. “Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future.”
The findings are not yet ready for clinical use. The researchers stress that the protein signatures need further validation in larger, more diverse populations before they could inform screening programmes or individual risk assessments. “Together with existing and future genetic evidence, these findings may help us identify biological pathways that could be targeted to prevent aggressive prostate cancer,” added Smith-Byrne.
The study adds to a growing body of research using proteomics—the large-scale study of proteins—to uncover early disease markers. For European health systems, where prostate cancer screening policies vary widely from country to country, such advances could eventually lead to more personalised approaches, sparing men with low-risk tumours from unnecessary treatment while focusing resources on those most likely to benefit.
As the continent grapples with ageing populations and rising healthcare costs, early detection tools that can distinguish indolent from aggressive cancers would be a significant step forward. The Oxford team’s work, while preliminary, points toward a future where a simple blood test might offer a decade or more of warning—and a chance to act before the disease takes hold.
